To date, six CAR T-cell therapies have been approved by the FDA, four of them targeting CD19-positive B-cell leukemias and lymphomas, and two targeting the B-cell maturation antigen (BCMA) expressed by multiple myeloma (11). Here, TNFRSF17 is linked to AL amyloidosis.